Cargando…

Associations of Interleukin 10, Matrix Metallopeptidase 9, and Legumain with Blood Pressure Variability and Neurologic Outcomes in Patients with Ischemic Stroke

BACKGROUND: Timely diagnosis and treatment are crucial to improve prognosis of ischemic stroke, making exploring factors associated with prognosis essential. Blood pressure variability (BPV) was reported to be associated with neurologic outcome, and basic researches on cardiovascular diseases found...

Descripción completa

Detalles Bibliográficos
Autores principales: Rong, Tianyi, He, Min, Hua, Yun, Chen, Deyan, Chen, Miao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751781/
https://www.ncbi.nlm.nih.gov/pubmed/33364822
http://dx.doi.org/10.2147/IJGM.S285003
_version_ 1783625725829447680
author Rong, Tianyi
He, Min
Hua, Yun
Chen, Deyan
Chen, Miao
author_facet Rong, Tianyi
He, Min
Hua, Yun
Chen, Deyan
Chen, Miao
author_sort Rong, Tianyi
collection PubMed
description BACKGROUND: Timely diagnosis and treatment are crucial to improve prognosis of ischemic stroke, making exploring factors associated with prognosis essential. Blood pressure variability (BPV) was reported to be associated with neurologic outcome, and basic researches on cardiovascular diseases found abnormal expression patterns of several factors including interleukin 10 (IL-10), matrix metallopeptidase 9 (MMP-9), and legumain which might be related to abnormal BPV but yet to prove in ischemic stroke. The study aimed to investigate whether IL-10, MMP-9, and legumain are associated with BPV and neurologic outcome of patients with ischemic stroke. PATIENTS AND METHODS: Newly diagnosed ischemic stroke patients admitted to the department of neurology, Shidong Hospital of Yangpu District in Shanghai between July 2017 and January 2019 were enrolled. IL-10, MMP-9, and legumain were detected and BPV was assessed within 72 hours after admission. All the patients were followed for neurologic outcomes at discharge and 6 months after admission based on the Modified Rankin Scale (MRS). Correlations of IL-10, MMP-9, and legumain with BPV were examined by Spearman correlation coefficient, and their associations with neurologic outcomes were evaluated by multivariable linear regression. RESULTS: A total of 349 patients with ischemic stroke were enrolled with an average age of 72.97±11.47 years. Compared with non-progressive ischemic stroke, patients with progressive ischemic stroke had significantly higher IL-10, MMP-9, and legumain on admission. MMP-9 was found to be positively correlated with BPV while no significant correlation was found for IL-10 and legumain with BPV. MMP-9 was associated with progressive ischemic stroke [β=0.23 (95% CI 0.11–0.35) per SD increase for MRS at discharge, and β=0.32 (95% CI 0.20–0.43) per SD increase for MRS at 6 months after admission]. CONCLUSION: Increased MMP-9 was associated with increased BPV and progressive ischemic stroke for patients with ischemic stroke, which might partially explain the effect of BPV on neurologic outcomes.
format Online
Article
Text
id pubmed-7751781
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77517812020-12-22 Associations of Interleukin 10, Matrix Metallopeptidase 9, and Legumain with Blood Pressure Variability and Neurologic Outcomes in Patients with Ischemic Stroke Rong, Tianyi He, Min Hua, Yun Chen, Deyan Chen, Miao Int J Gen Med Original Research BACKGROUND: Timely diagnosis and treatment are crucial to improve prognosis of ischemic stroke, making exploring factors associated with prognosis essential. Blood pressure variability (BPV) was reported to be associated with neurologic outcome, and basic researches on cardiovascular diseases found abnormal expression patterns of several factors including interleukin 10 (IL-10), matrix metallopeptidase 9 (MMP-9), and legumain which might be related to abnormal BPV but yet to prove in ischemic stroke. The study aimed to investigate whether IL-10, MMP-9, and legumain are associated with BPV and neurologic outcome of patients with ischemic stroke. PATIENTS AND METHODS: Newly diagnosed ischemic stroke patients admitted to the department of neurology, Shidong Hospital of Yangpu District in Shanghai between July 2017 and January 2019 were enrolled. IL-10, MMP-9, and legumain were detected and BPV was assessed within 72 hours after admission. All the patients were followed for neurologic outcomes at discharge and 6 months after admission based on the Modified Rankin Scale (MRS). Correlations of IL-10, MMP-9, and legumain with BPV were examined by Spearman correlation coefficient, and their associations with neurologic outcomes were evaluated by multivariable linear regression. RESULTS: A total of 349 patients with ischemic stroke were enrolled with an average age of 72.97±11.47 years. Compared with non-progressive ischemic stroke, patients with progressive ischemic stroke had significantly higher IL-10, MMP-9, and legumain on admission. MMP-9 was found to be positively correlated with BPV while no significant correlation was found for IL-10 and legumain with BPV. MMP-9 was associated with progressive ischemic stroke [β=0.23 (95% CI 0.11–0.35) per SD increase for MRS at discharge, and β=0.32 (95% CI 0.20–0.43) per SD increase for MRS at 6 months after admission]. CONCLUSION: Increased MMP-9 was associated with increased BPV and progressive ischemic stroke for patients with ischemic stroke, which might partially explain the effect of BPV on neurologic outcomes. Dove 2020-12-16 /pmc/articles/PMC7751781/ /pubmed/33364822 http://dx.doi.org/10.2147/IJGM.S285003 Text en © 2020 Rong et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Rong, Tianyi
He, Min
Hua, Yun
Chen, Deyan
Chen, Miao
Associations of Interleukin 10, Matrix Metallopeptidase 9, and Legumain with Blood Pressure Variability and Neurologic Outcomes in Patients with Ischemic Stroke
title Associations of Interleukin 10, Matrix Metallopeptidase 9, and Legumain with Blood Pressure Variability and Neurologic Outcomes in Patients with Ischemic Stroke
title_full Associations of Interleukin 10, Matrix Metallopeptidase 9, and Legumain with Blood Pressure Variability and Neurologic Outcomes in Patients with Ischemic Stroke
title_fullStr Associations of Interleukin 10, Matrix Metallopeptidase 9, and Legumain with Blood Pressure Variability and Neurologic Outcomes in Patients with Ischemic Stroke
title_full_unstemmed Associations of Interleukin 10, Matrix Metallopeptidase 9, and Legumain with Blood Pressure Variability and Neurologic Outcomes in Patients with Ischemic Stroke
title_short Associations of Interleukin 10, Matrix Metallopeptidase 9, and Legumain with Blood Pressure Variability and Neurologic Outcomes in Patients with Ischemic Stroke
title_sort associations of interleukin 10, matrix metallopeptidase 9, and legumain with blood pressure variability and neurologic outcomes in patients with ischemic stroke
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751781/
https://www.ncbi.nlm.nih.gov/pubmed/33364822
http://dx.doi.org/10.2147/IJGM.S285003
work_keys_str_mv AT rongtianyi associationsofinterleukin10matrixmetallopeptidase9andlegumainwithbloodpressurevariabilityandneurologicoutcomesinpatientswithischemicstroke
AT hemin associationsofinterleukin10matrixmetallopeptidase9andlegumainwithbloodpressurevariabilityandneurologicoutcomesinpatientswithischemicstroke
AT huayun associationsofinterleukin10matrixmetallopeptidase9andlegumainwithbloodpressurevariabilityandneurologicoutcomesinpatientswithischemicstroke
AT chendeyan associationsofinterleukin10matrixmetallopeptidase9andlegumainwithbloodpressurevariabilityandneurologicoutcomesinpatientswithischemicstroke
AT chenmiao associationsofinterleukin10matrixmetallopeptidase9andlegumainwithbloodpressurevariabilityandneurologicoutcomesinpatientswithischemicstroke